alexa Pharmacogenomics: A Step towards Advancing Clinical Trials | OMICS International
ISSN: 2153-0645
Journal of Pharmacogenomics & Pharmacoproteomics

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Pharmacogenomics: A Step towards Advancing Clinical Trials

Prashant Pandya*

Reliance Life Sciences, Mumbai, India

*Corresponding Author:
Dr. Prashant Pandya
Reliance Life Sciences, Mumbai, India
Tel: 91 9967017172
E-mail: [email protected]

Received Date: March 28, 2017; Accepted Date: March 29, 2017; Published Date: April 05, 2017

Citation: Pandya P (2017) Pharmacogenomics: A Step towards Advancing Clinical Trials. J Pharmacogenomics Pharmacoproteomics 8:e157. doi: 10.4172/2153- 0645.100e157

Copyright: © 2017 Pandya P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pharmacogenomics & Pharmacoproteomics

Pharmacogenomics testing is a step towards advancing clinical trials, new product development and clinical practice. It permit drugs to be made tailor made for individual and studied as per generic makeup because some genes are responsible for drug effect. This will help to create personalized medicine with grater efficacy and safety by understanding genetic makeup of patients.

Our body has millions of genes. Testing of Drug-Gene is called as “Pharmacogenomics”. Effect of Gene is studied after administration of drug during clinical trial. Genetic information is used to study the individual response as drugs are available for all but doesn’t give similar response so it is difficult to know who will benefit or who will experience adverse drug reaction. Pharmacogenomics will help to make clinical decision based on genetics and accordingly dosage or different drug will be selected [1-7].

Pharmacogenomics allow early identification of signals of predictive information, it doesn’t improve efficacy but provide useful information to the developers that who are likely to be responder and thus overall improve the drug development speed in clinical trials (Figure 1).

Below is the Limitation of Pharmacogenomics Testing in Clinical Testing

• One single test can’t serve the purpose for all.

• Pharmacogenomic testing is not currently available for all medications as human share around 99.5% genomes and remaining 0.5% differ and responsible for our susceptibility to disease and drug response.

• It is expensive and time consuming to do such testing.

• It is difficult to extrapolate such testing in healthcare setting.

• Drug response is also affected by interacting genetic and environmental factors.

• Many times multiple genetic variants are responsible for the response.


• People respond differently to various medicines. With better understanding of disease help to develop efficient treatment. Pharmacogenomics testing will help in future to develop tailored made drugs, a form of personalized medicine having very less adverse drug reactions and help to identify drug that will best treat disease.

• It is advisable to include pharmacogenomics during early phase clinical trials which help to reduce overall development time and drug can be market earlier by doing clinical trial on less subjects.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 770
  • [From(publication date):
    April-2017 - Jun 24, 2018]
  • Breakdown by view type
  • HTML page views : 692
  • PDF downloads : 78

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7